![[SEN]C&Pharm develops injections for severely ill patients with COVID-19](https://img.sedaily.com/web/common/sedaily.jpg "[SEN]C&Pharm develops injections for severely ill patients with COVID-19")
[서울경제TV=배요한기자] Hyundai Bio (048410)Science succeeded in developing’Poly-COV01′, an injection drug for the treatment of severe patients with novel coronavirus infection (Corona 19), by C&Pharm, the major shareholder, and acting as a clinical agency for emergency use approval with’DT&CRO’, a clinical consignment organization (CRO). It announced that the contract was signed on the 23rd.
Poly-COV01 is an oral drug among corona19 patients like Feramivir, an injection drug that emerged as the last hope for severely ill patients who were unable to take the oral drug Tamiflu, who was injured as a game changer during the’swine flu’ crisis in 2009. It was developed for very few severely ill patients who could not even administer nasal inhalation drugs, C&Pharm said.
C&Pharm is a drug in which Poly-COV01 improves the short half-life of the blood concentration of nikolasamide based on its’pain-free anticancer drug’ platform. By controlling the number of administrations, virus proliferation is prevented throughout the treatment period. It was developed with the aim of maintaining’IC100′, an effective concentration in blood that suppresses 100%, and it is characterized by minimizing side effects due to drug toxicity, he explained.
Niclosamide, the base drug of Poly-COV01, was selected as the No. 1 candidate for COVID-19 treatment among major drugs in the world by Institut Pasteur Korea in April of this year.It is known in the pharmaceutical world that it can be applied to various diseases such as cancer and diabetes in addition to corona virus diseases. .
C&Pharm expects that Poly-COV01 can be the last’hopeful injection’ for severely ill patients with Corona 19, who are currently at the crossroads of life and death. Under the policy of conducting the clinical procedure of Poly-COV01 as quickly as possible, the effect of the injection was tested with the relevant authorities. We are discussing the schedule.
Hyundai Bio is pursuing a plan to provide priority supply of Poly-COV01 to severely ill patients who are further driven into the blind spot of treatment due to the’third coronavirus pandemic’ after receiving approval for treatment purposes so that they can administer Poly-COV01 before market approval by the authorities. . ‘Therapeutic Use Approval’ is a system that allows new drugs in the clinical stage prior to new drug approval to be administered to patients with incurable diseases or terminal cancer, and the’Expanded Access Program’ of the US Food and Drug Administration (FDA). Is similar to
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >